Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial

David Silvers(Universal Sensors (United States)), Alan F. Joslyn(Janssen (United States)), Yin Liu(Janssen (United States)), Eamonn M.M. Quigley(Methodist Hospital), Christina Farup(Janssen (United States)), Mark Kipnes(Diabetes & Glandular Disease Clinic), Vasti L. Broadstone(University of Louisville Hospital), Richard W. McCallum(Texas Tech University), Nancy Kline Leidy(Health Outcomes Solutions (United States)), David Patterson(Virginia Mason Medical Center)
Clinical Therapeutics
May 1, 1998
10.1016/s0149-2918(98)80054-4
Cited by 146

Related Papers

Development and first validation of the COPD Assessment Test
|European Respiratory Journal|2009|3.2k
Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study
|Gastroenterology|2020|2.1k
Content Validity—Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 2—Assessing Respondent Understanding
|Value in Health|2011|1.1k
Content Validity—Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 1—Eliciting Concepts for a New PRO Instrument
|Value in Health|2011|1.1k
Irritable bowel syndrome
|Nature Reviews Disease Primers|2016|981